39P Preliminary clinical investigations and mechanism exploration of furmonertinib in NSCLC with EGFR exon 20 insertion

医学 奥西默替尼 内科学 第一行 肿瘤科 胃肠病学 外科 表皮生长因子受体 癌症 埃罗替尼
作者
X. Zhang,G. Feng,H. Han,B. Dong,Y. Yang,H. Zhu,S. Fan,H. Tang
出处
期刊:Journal of Thoracic Oncology [Elsevier BV]
卷期号:18 (4): S63-S63
标识
DOI:10.1016/s1556-0864(23)00293-9
摘要

Here we analyzed the clinical efficacy of furmonertinib, a novel 3rd generation EGFR TKI, in advanced NSCLC patients (pts) who harboring EGFRex20ins and explored mechanism. A retrospective single-arm analysis was performed to evaluate the efficacy of 20 NSCLC pts harboring EGFRex20ins receiving furmonertinib treatment from three institutions. Meanwhile, we investigated the clinical efficacy of furmonertinib versus osimertinib as second-line treatment, because pts about furmonertinib as first-line treatment were immature. In addition, the binding activity of different EGFR TKIs to EGFRex20ins were computationally constructed based on the crystal structure of EGFR_D770_N771insNPG/V948R (PDB ID: 7LGS) by the Schrödinger software (2021–2 Release). Of the 20 pts selected, we found that EGFRex20ins p. S768_D770dup (n = 5) variants were more common. Six first-line pts all achieved PR (ORR: 100%), five of the eight second-line pts achieved PR (ORR: 62.5%), and three of the six multiple-line pts achieved PR (ORR: 50.0%). We observed 14 pts with PR and six pts with SD as best response to furmonertinib (ORR: 70.0%, DCR: 100%). All pts showed tumor shrinkage in target lesions (median best percent change, –36.43% [–74.78%, –5.56%]). Median PFS was 10.2 (95% CI, 7.19–13.21) months (mo). Median DOR was 8.5 (95% CI, 4.97–12.03) mo. Comparative analysis of the efficacy of different groups showed that median PFS was significantly longer in furmonertinib group than in osimertinib (10.2 vs 3.8 mo, p = 0.008). Median OS was numerically longer in furmonertinib group than in osimertinib (18.9 vs 11.7 mo, p = 0.207). No grade 3 or above adverse events were observed. Furthermore, rather than erlotinib (GlideScore: –5.564; MM/GBSA: –52.8044), gefitinib (–7.68; –47.317), and afatinib (–5.075; –44.64), furmonertinib (–11.085; –68.1575) and osimertinib (–10.031; –63.87) revealed favorable binding activity to EGFRex20ins, with furmonertinib being the most significant. Furmonertinib has positive clinical efficacy to advanced NSCLC pts with EGFRex20ins probably based on its favorable binding activity to EGFRex20ins. Furmonertinib may be the optimal choice for these pts in the future.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
夏夏完成签到,获得积分20
2秒前
氮化硼小兵完成签到,获得积分10
2秒前
拾壹完成签到,获得积分10
3秒前
友好语风完成签到,获得积分10
4秒前
酷酷依秋完成签到,获得积分10
4秒前
liu完成签到 ,获得积分10
5秒前
土豆完成签到,获得积分10
6秒前
Lanny完成签到 ,获得积分10
8秒前
ooa4321完成签到,获得积分10
9秒前
9秒前
CLTTTt完成签到,获得积分10
10秒前
drizzling完成签到,获得积分10
11秒前
曦夜完成签到,获得积分10
12秒前
小二郎应助Tin采纳,获得10
14秒前
愛愛愛愛发布了新的文献求助10
14秒前
桃花源的瓶起子完成签到 ,获得积分10
16秒前
楚寅完成签到 ,获得积分10
17秒前
Yang完成签到 ,获得积分10
19秒前
丫头完成签到 ,获得积分10
19秒前
耿教授完成签到,获得积分20
21秒前
21秒前
狂野未来完成签到,获得积分10
24秒前
phoenix001完成签到,获得积分0
27秒前
七米日光完成签到 ,获得积分10
27秒前
chaosyw完成签到,获得积分10
27秒前
故意的问安完成签到 ,获得积分10
29秒前
仗炮由纪完成签到,获得积分10
33秒前
笑一笑完成签到 ,获得积分10
34秒前
仗炮由纪发布了新的文献求助20
36秒前
费城青年完成签到,获得积分10
37秒前
perway完成签到,获得积分20
37秒前
隐形曼青应助瞿寒采纳,获得10
38秒前
lxlcx完成签到,获得积分0
41秒前
研友_VZGVzn完成签到,获得积分10
45秒前
46秒前
48秒前
瞿寒发布了新的文献求助10
51秒前
Tin完成签到,获得积分10
52秒前
愛愛愛愛完成签到,获得积分10
53秒前
LiChard完成签到 ,获得积分10
54秒前
高分求助中
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Technical Brochure TB 814: LPIT applications in HV gas insulated switchgear 1000
Immigrant Incorporation in East Asian Democracies 600
Nucleophilic substitution in azasydnone-modified dinitroanisoles 500
不知道标题是什么 500
A Preliminary Study on Correlation Between Independent Components of Facial Thermal Images and Subjective Assessment of Chronic Stress 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3968578
求助须知:如何正确求助?哪些是违规求助? 3513391
关于积分的说明 11167428
捐赠科研通 3248822
什么是DOI,文献DOI怎么找? 1794499
邀请新用户注册赠送积分活动 875116
科研通“疑难数据库(出版商)”最低求助积分说明 804664